would you give it up already. why such a grudge against this company. they accomplished more than most biotechs today. they just got an approved drug. who cares if it goes down today. long term this will be over 10 again ..
Its early bozo. Think the stock will go over 8. If not we wait for sales to roll in and who knows maybe a buyout down the road now that they have a drug to sell now.. Your short position imo wont make you much from here.
I have no doubt. My bet is dilution around the corner. They could sell 7 million shares at 3 , raise another
21 million. That will keep Spiro going for a couple more years. The sad part is people will actually buy the
dilution. Look at what 10000 dollars of CYCC stock was 10 years ago and look what it is worth now. Truly
sad Hind sight is 20/20 but we all should have bought CPXX.. $1 to 30 now...
regardless of last weeks news imo this has created an awesome buying opportunity. Buy in the 20's ..
the 19.59 price on friday was the low. never even should have traded there. i love when wall street and people throw in the towel due to fear. pipeline bigger than ever lots of cash partnerships. this will be 30-40
again this year.
just my opinion. If you think a $2 stock in late pIII trials with a market cap in excess
of 100 million is going to be a success then I have swampland in florida to sell you.
also people like you who throw childish remarks and who are naiive cant have more than a couple hundred bucks to there name.
say what you will about me rookie. get back to me if or when CYTR falls nicely below $1. Im telling you low price and low market cap this late in the game means disaster. CPXX was the only
lottery ticket which defied the odds. I feel bad for the patients who could use a good drug for
the disease. imo CYTR is not the one and you will read imo the following headline as usual PIII
drug did not meet its primary endpoint. sadly this will just be another CYCC THLD etc.
so even if they dilute 1 or 2 more times and even had a share count at 50 million . at $10 a share you have a 500 million cap which can be justified with 100-200 million in annual sales.